Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget Byrd, J. C., Smith, S., Wagner-Johnston, N., Sharman, J., Chen, A. I., Advani, R., Augustson, B., Marlton, P., Commerford, S. R., Okrah, K., Liu, L., Murray, E., Penuel, E., Ward, A. F., Flinn, I. W. 2019; 10 (38): 3827–30

Abstract

[This corrects the article DOI: 10.18632/oncotarget.24310.].

View details for DOI 10.18632/oncotarget.27011

View details for PubMedID 31217910